Clinical trials
Refractory clinical trials
Below are recruiting refractory clinical trials, each written for real people, not researchers. We’re tracking 1,203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
Westwood, KansasAges 18 years+ - NCT05651932RecruitingPhase 1
Test of an MMSET inhibitor for relapsed multiple myeloma
This Phase 1 trial tests a new drug that targets MMSET in people whose multiple myeloma has returned or not responded to prior treatment. It aims to find a safe dose and see whether it can shrink myeloma in this setting.
San Francisco, CaliforniaAges 18 years+ - NCT05669430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug alone and with pembrolizumab
This early-phase study tests GV20-0251 (an anti-cancer treatment) by itself and combined with pembrolizumab, to see how well it works and how safe it is. It is for adults with advanced solid tumors that have grown despite standard treatments, or where standard treatments aren’t an option.
Los Angeles, CaliforniaAges 18 years+ - NCT05674552RecruitingPhase 2/Phase 3
Ketone drinks to treat hard-to-stop seizure emergencies
This trial tests whether taking ketone esters (a special form of ketones) can help stop refractory generalized convulsive status epilepticus (a seizure emergency that is hard to control). If you qualify, the study team will check safety closely, especially your breathing, heart stability, and blood sugar/acid levels.
SohagAges 1–10 - NCT05681195RecruitingPhase 2
Zanubrutinib plus pemetrexed for recurrent brain lymphomas
This trial tests zanubrutinib (a targeted lymphoma medicine) together with pemetrexed (chemotherapy) for lymphoma that has come back or did not respond well in or around the brain. It may help shrink measurable lymphoma and improve control of disease after prior treatments.
Miami, FloridaAges 18 years+ - NCT05684731RecruitingPhase 1
Test drug KM1 for repeat or resistant ovarian cancer
This early-phase study tests whether KM1 is safe and can shrink or control ovarian, fallopian tube, or primary peritoneal cancer that has come back or not responded to standard treatment. It may help people who have limited options, but eligibility is strict to keep participants safe.
Wuhan, HubeiAges 18 years+ - NCT05696522Recruiting
Radiation to treat hard-to-control dangerous heart rhythm
This trial tests a focused type of radiation to treat ventricular tachycardia (VT) that keeps coming back despite other treatments. It may help people who cannot (or do not want to) have the usual catheter procedure to fix the rhythm.
LondonAges 18–85 - NCT05701306RecruitingPhase 1
Testing a new medicine for hard-to-treat childhood tumors
This Phase 1 trial tests APG-115 alone or with another drug (APG-2575) in children whose neuroblastoma or other solid tumors have come back or did not respond to treatment. It aims to find a safe dose and see how well the treatment works in these tumors.
Guangzhou, GuangdongAges 12–18 - NCT05713214Recruiting
Long-term follow-up after a gene-modified cell treatment
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
Memphis, TennesseeAges Any age - NCT05726396RecruitingPhase 2
Microbiome therapy for steroid-resistant immune colitis
This Phase 2 pilot study tests a “restorative microbiota therapy” (RMT) to treat colitis caused by immune checkpoint inhibitors when standard treatments like steroids are not working. It aims to see if this approach is safe and practical, and may improve diarrhea and gut inflammation.
Brainerd, MinnesotaAges 18 years+ - NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT05733013Recruiting
Using redifferentiation medicines before radioactive iodine for thyroid cancer
This study collects information on how redifferentiation medicines used before radioactive iodine work in everyday care for certain thyroid cancers that are unlikely to respond to radioactive iodine. It may help doctors understand the best real-world way to use these medicines to plan and deliver treatment.
New York, New YorkAges 18 years+ - NCT05734066RecruitingPhase 1/Phase 2
Lurbinectedin drug study for young people with Ewing sarcoma
This trial tests lurbinectedin, a cancer medicine, by itself (no other drugs) in children and young adults whose Ewing sarcoma has come back or did not respond to prior treatment. It aims to see how safe the drug is and whether it can help control the cancer.
Los Angeles, CaliforniaAges 2–30 - NCT05735184RecruitingPhase 1
Ziftomenib with AML medicines for NPM1- or KMT2A-mutated leukemia
This Phase 1 trial tests how safe and tolerable ziftomenib is when combined with standard AML medicines (like venetoclax and azacitidine, and other chemo options) in people with AML. It’s for AML patients who have specific genetic changes (NPM1 mutation or KMT2A rearrangement) and helps doctors find the best, safest dose plan.
Phoenix, ArizonaAges 18 years+ - NCT05749588RecruitingPhase 2
Study for advanced triple-negative breast cancer after prior treatments
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
ShanghaiAges 18 years+ - NCT05765175Recruiting
Radioablation versus repeat ablation for hard-to-treat VT
This trial compares a heart procedure using targeted radiation (called radioablation) to a repeat catheter ablation for people with high-risk, hard-to-control ventricular tachycardia (VT). It aims to find which approach is safer and works better after standard ablation and amiodarone have not stopped the abnormal rhythm.
Los Angeles, CaliforniaAges 18 years+ - NCT05766748RecruitingPhase 1/Phase 2
Azeliragon trial for pancreatic cancer after prior treatments failed
This trial tests azeliragon in people whose pancreatic cancer has spread or grown locally and who did not respond well to earlier chemotherapy. It aims to see whether the drug can help control the cancer and be tolerated after prior treatment.
Los Angeles, CaliforniaAges 18–80 - NCT05768932RecruitingPhase 1
Study drug for advanced cancers or relapsed AML
This Phase 1 trial tests BAL0891, a new study treatment, in people with advanced solid tumors that have run out of treatment options, or in relapsed/refractory acute myeloid leukemia (AML). The goal is to find a safe dose and see how well it may work in these hard-to-treat cancers.
New Haven, ConnecticutAges 18 years+ - NCT05773040RecruitingPhase 1
CAR T-cell therapy made from your own immune cells
This Phase 1 trial tests an “autologous” CAR T-cell treatment (made from your own T cells) that targets a cancer marker called CD79b in certain relapsed or hard-to-treat B-cell lymphomas. It’s designed to find a safe dose and see whether the treatment can shrink tumors and help control the lymphoma after prior therapies.
Houston, TexasAges 18 years+ - NCT05788120Recruiting
Study heart rhythm problems in adults on VA ECMO
This study looks at how often abnormal heart rhythms happen and how serious they are in adults who are supported with VA ECMO for severe heart failure. It mainly involves using medical information, aiming to better understand complications in this critical situation.
AngersAges 18 years+ - NCT05791448RecruitingPhase 1
AU409 for advanced liver cancers or liver-spread tumors
This Phase 1 trial studies AU409, a new medicine, for advanced primary liver cancers or other solid tumors mainly in the liver. It aims to find a safe dose and see how well the treatment works for people whose usual options have not worked or are not available.
Los Angeles, CaliforniaAges 18 years+ - NCT05794958RecruitingPhase 1
Safety of second CAR-T re-infusion for hard-to-treat lymphoma
This Phase 1 study tests whether a second re-infusion of axicabtagene ciloleucel (CAR-T) is safe in people with aggressive B-cell non-Hodgkin lymphoma that came back or did not respond after standard second-line CAR-T. It may help some patients by trying to improve disease control while carefully monitoring side effects.
Palo Alto, CaliforniaAges 18 years+ - NCT05798897RecruitingPhase 1
Study drug MT-601 for relapsed lymphoma patients
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
Duarte, CaliforniaAges 18–100 - NCT05801913RecruitingPhase 1
Personalized immune cell therapy plus a CMV vaccine
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
Duarte, CaliforniaAges 18 years+
Hear when a new Refractory trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for refractory?
- Yes. Clin2 currently lists 1,203 recruiting refractory studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a refractory trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a refractory trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.